Product Reports Resources Pricing Login Book a demo

Prexton therapeutics

Biotech & Life Sciences · Oss, Netherlands · Founded 2012

Integrates molecular, behavioral and chemistry technologies to address Parkinson’s disease and other brain disorders MoreLess

Prexton Therapeutics is dedicated to developing innovative drugs aimed at improving the quality of life for individuals suffering from brain disorders and other diseases. The company specializes in designing novel mGluR4 compounds, which are a new class of treatments for these conditions. Prexton Therapeutics primarily serves patients with neurological disorders, operating within the pharmaceutical and biotech market. The business model revolves around research and development of proprietary compounds, which are then licensed or sold to larger pharmaceutical companies for further development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from sales of the developed drugs.

Keywords: mGluR4, brain disorders, neurological, innovative drugs, biotech, pharmaceutical, R&D, licensing, proprietary compounds, quality of life.

Valuation $1–2.5B
Headcount <100
Total funding $10–50M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Prexton therapeutics and the history behind them.
Power Law Unicorn$1–10B valuation tier

Talent graph

Prexton therapeutics's talent

Book a demo to see the people
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Prexton therapeutics's cap table

Sourced from Dealroom's funding history.

Seed 1 investor entered at this stage
Eclosion
Series A 4 investors entered at this stage
Ysios Capital
M Ventures
Seroba Life Sciences
Forbion Capital Partners
Series B+ 2 investors entered at this stage
Seroba Life Sciences
Forbion Capital Partners

Global footprint

Where Prexton therapeutics has talent and traffic

Workforce by country
🇳🇱 Netherlands · Oss HQ
Book a demo for the full country breakdown
Web traffic by country
1.1K monthly visits
across markets
🇺🇸 United States45.5%
🇲🇪 Montenegro18.2%
🇩🇪 Germany18.2%
🇧🇪 Belgium9.1%
Top 4 markets shown

Patent intelligence

$26k patent portfolio · 2 active families

Estimated portfolio value
$26k
<0.01% of valuation · 1620.9× smaller than top peer Voyager Therapeutics ($42M)
2 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Prexton therapeutics

An AI-synthesized read of the highest-engagement posts about Prexton therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prexton therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles